Correspondence 0001628280-24-047103 from Context Therapeutics Inc. (CNTX) (CIK 0001842952) (CNTX)
Context Therapeutics Inc. (CNTX) (CIK 0001842952)
Date: Nov. 12, 2024 · CIK: 0001842952 · Accession: 0001628280-24-047103
AI Filing Summary & Sentiment
File numbers found in text: 333-283037
Letter
Document
Context Therapeutics Inc.
2001 Market Street, Suite 3915, Unit #15
Philadelphia, Pennsylvania 19103
November 12, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Context Therapeutics Inc.
Registration Statement on Form S-3
File No. 333-283037
Ladies and Gentlemen:
Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of Context Therapeutics Inc., respectfully requests that the effective date of the Registration Statement on Form S-3 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on November 14, 2024, or as soon as practicable thereafter.
If you have any questions or require additional information, please contact Griffin D. Foster of Faegre Drinker Biddle & Reath LLP at (317) 569-4843. Thank you for your assistance and cooperation in this matter.
Very truly yours,
CONTEXT THERAPEUTICS INC.
Show Raw Text
CORRESP 1 filename1.htm Document Context Therapeutics Inc. 2001 Market Street, Suite 3915, Unit #15 Philadelphia, Pennsylvania 19103 November 12, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Context Therapeutics Inc. Registration Statement on Form S-3 File No. 333-283037 Ladies and Gentlemen: Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of Context Therapeutics Inc., respectfully requests that the effective date of the Registration Statement on Form S-3 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on November 14, 2024, or as soon as practicable thereafter. If you have any questions or require additional information, please contact Griffin D. Foster of Faegre Drinker Biddle & Reath LLP at (317) 569-4843. Thank you for your assistance and cooperation in this matter. Very truly yours, CONTEXT THERAPEUTICS INC. By: /s/ Martin Lehr Martin Lehr Chief Executive Officer cc: Jennifer Minai-Azary, Chief Financial Officer, Context Therapeutics Inc. Alex Levit, Chief Legal Officer, Context Therapeutics Inc. Walter J. Mostek, Faegre Drinker Biddle & Reath LLP Griffin D. Foster, Faegre Drinker Biddle & Reath LLP